TCI Wealth Advisors’s CorMedix CRMD Stock Holding History

TCI Wealth Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-160	Closed	-$2K	–	1427
2018 Q4	$2K	Buy	+160	New	+$1.07K	﹤0.01%	973

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TCI Wealth Advisors's CRMD Position: Q2 2023 in Review

TCI Wealth Advisors sold out of CorMedix (CRMD) in Q2 2023, closing a stake of 100 shares — an estimated $414 sold.

TCI Wealth Advisors first reported a position in CRMD in Q2 2015 and held it in 32 quarters. The position peaked at $18K in Q1 2019. 86 funds tracked by Wall St. Rank hold CRMD as of Q2 2023.

TCI Wealth Advisors reported no remaining CorMedix position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 100 CorMedix shares in Q2 2023, an estimated $414.
TCI Wealth Advisors first reported a position in CorMedix in Q2 2015 and held it in 32 quarters.
TCI Wealth Advisors's CorMedix position peaked at $18K in Q1 2019.
86 funds tracked by Wall St. Rank held CorMedix as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.